The aim of the study is to evaluate the safety and efficacy of a 3- and 5-day course of levamisole (2.5 mg/kg) in management of loiasis microfilaremia.
Consent informed, written, signed and dated
Women or men aged 18 to 65 years inclusive
Carrier of L. loa microfilaremia
Body weight ≥ 40 kg in women and ≥ 45 kg in men; and less than 90 kg
Participation in any study other than a purely observational study, within the 4 weeks preceding this study (determined by the theoretical date of the first administration of levamisole or placebo)
Any vaccination within 4 weeks previous to this study
Infection requiring treatment in the 10 days previous to this study, as determined by the anamnesis during the medical interview (e.g. pulmonary infection , digestive or skin infection; with or without antibiotic treatment)
Treatment with clozapine, phenothiazines, sulfasalazine, carbamazepine, synthetic antithyroid drugs, ticlopidine, cimetidine, and gold salts: whether it was long-term treatment, or treatment given as a single dose 10 days before the start of treatment for the clinical trial (precaution with regard to the risk of agranulocytosis of immuno-allergic or toxic origin)
Programme National de Lutte contre l'Onchocercose, Republic of the Congo
Lead sponsor
Institut de Recherche pour le Developpement
Collaborator